FDA approves new nail fungus treatment

FDA approves new nail fungus treatment

(HealthDay)—A new topical nail fungus treatment, Jublia, has been approved by the U.S. Food and Drug Administration.

Jublia (efinaconazole) is made by the Canadian company Valeant Pharmaceuticals International Inc., the Associated Press reported Wednesday.

Jublia comes in liquid form and is applied directly to the nail. According to Valeant, FDA approval was based on two studies involving more than 1,600 people with onychomycosis. The findings were published last year in the Journal of the American Academy of Dermatology. Cure rates were about 18 percent for the patients involved in one study, and about 15 percent for those involved in the other.

In a statement, Valeant said it plans to begin marketing Jublia late in 2014.


Explore further

Topical treatment effective for toenail fungal infection

More information: Health Highlights: June 11, 2014

Copyright © 2014 HealthDay. All rights reserved.

Citation: FDA approves new nail fungus treatment (2014, June 12) retrieved 17 May 2021 from https://medicalxpress.com/news/2014-06-fda-fungus-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments